Table 1 Relationship between HMGB1 expression and clinicopathologic features in a validated cohort
|
Clinicopathologic features |
Low expression, n = 18 (%) |
High expression, n = 18 (%) | P-value |
|---|---|---|---|
| Age (years) | |||
| < 45 | 9 (50%) | 10 (55.6%) | P = 0.738 |
| ≥ 45 | 9 (50%) | 8 (44.4%) | |
| Gender | |||
| Male | 7 (66.7%) | 8 (22.2%) | P = 0.597 |
| Female | 11 (33.3%) | 10 (77.8%) | |
| Tumor size (cm) | |||
| < 1 | 12 (66.7%) | 6 (33.3%) | P = 0.046 |
| ≥ 1 | 6 (33.3%) | 12 (66.7%) | |
| Lymph node metastasis | |||
| No | 13 (72.2%) | 6 (33.3%) | P = 0.019 |
| Yes | 5 (27.8%) | 12 (66.7%) | |
| Histological type | |||
| PTC | 9 (50%) | 10 (55.6%) | P = 0.738 |
| FTC | 9 (50%) | 8 (44.4%) | |
| Clinical stage | |||
| I + II | 13 (72.2%) | 7 (38.9%) | P = 0.044 |
| III + IV | 5 (27.8%) | 11 (61.1%) | |